Crestone’s antibiotic cures C. diff infections and prevents recurrence better than vancomycin in phase 2

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within a couple of months. It also often resists antibiotic treatment, leaving it free to infect the colon and cause diarrhea, nausea, fever and, in severe cases, sepsis and death.

Boulder, Colorado-based biotech Crestone is going after C. diff with a new antimicrobial, CRS3123. In a phase 2 study, the company reports that its drug cured 28 of 29 patients within 12 days, similar to the 13 of 14 cured patients who received the antibiotic vancomycin. 

But CRS3123 stood out by stopping C. diff’s notorious comebacks: After 40 days, just 4% of patients who received Crestone’s drug had their infections return, compared to 23% in the vancomycin group.

The cure rate at Day…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks